Compare GM & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GM | TAK |
|---|---|---|
| Founded | 1908 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1B | 59.8B |
| IPO Year | 2010 | 2007 |
| Metric | GM | TAK |
|---|---|---|
| Price | $86.34 | $21.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 3 |
| Target Price | ★ $101.09 | $22.74 |
| AVG Volume (30 Days) | ★ 7.8M | 3.0M |
| Earning Date | 10-20-2026 | 10-29-2026 |
| Dividend Yield | 0.81% | ★ 1.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.94 | N/A |
| Revenue | ★ $185,019,000,000.00 | N/A |
| Revenue This Year | $0.71 | $4.54 |
| Revenue Next Year | $1.68 | $2.37 |
| P/E Ratio | ★ $11.17 | $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $67.06 | $13.91 |
| 52 Week High | $93.70 | $21.73 |
| Indicator | GM | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 67.52 |
| Support Level | $84.16 | $17.73 |
| Resistance Level | $88.02 | $21.73 |
| Average True Range (ATR) | 2.72 | 0.37 |
| MACD | 0.36 | -0.01 |
| Stochastic Oscillator | 60.34 | 76.18 |
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under three segments: GM North America, GM International, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its US market share leadership in 2022, after losing it to Toyota due to the chip shortage in 2021. 2025 US share was 17.4%, up 60 basis points from 2024. The Cruise autonomous vehicle arm, which GM now owns outright, previously operated driverless geofenced AV robotaxi services in San Francisco and other cities, but after a 2023 accident, GM decided that it will focus on personal AVs. GM Financial became the company's captive finance arm in 2010 via the purchase of AmeriCredit.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.